Literature DB >> 17618469

3D-QSAR studies on fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors by CoMFA and CoMSIA.

Juan Zeng1, Guixia Liu, Yun Tang, Hualiang Jiang.   

Abstract

Three-dimensional quantitative structure-activity relationship (3D-QSAR) analyses using CoMFA and CoMSIA methods were conducted on a series of fluoropyrrolidine amides as dipeptidyl peptidase IV (DP-IV) inhibitors. The selected ligands were docked into the binding site of the 3D model of DP-IV using the GOLD software, and the possible interaction models between DP-IV and the inhibitors were obtained. Based on the binding conformations of these fluoropyrrolidine amides and their alignment inside the binding pocket of DP-IV, predictive 3D-QSAR models were established by CoMFA and CoMSIA analyses, which had conventional r2 and cross-validated coefficient values ([Formula: see text]) up to 0.982 and 0.555 for CoMFA and 0.953 and 0.613 for CoMSIA, respectively. The predictive ability of these models was validated by six compounds that were in the testing set. Structure-based investigations and the final 3D-QSAR results provide the guide for designing new potent inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17618469     DOI: 10.1007/s00894-007-0221-8

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  27 in total

1.  Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001.

Authors:  Ali H Mokdad; Earl S Ford; Barbara A Bowman; William H Dietz; Frank Vinicor; Virginia S Bales; James S Marks
Journal:  JAMA       Date:  2003-01-01       Impact factor: 56.272

2.  The reversed binding of beta-phenethylamine inhibitors of DPP-IV: X-ray structures and properties of novel fragment and elaborated inhibitors.

Authors:  Sonja Nordhoff; Silvia Cerezo-Gálvez; Achim Feurer; Oliver Hill; Victor G Matassa; Günther Metz; Christian Rummey; Meinolf Thiemann; Paul J Edwards
Journal:  Bioorg Med Chem Lett       Date:  2006-01-11       Impact factor: 2.823

3.  Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog.

Authors:  Hanne B Rasmussen; Sven Branner; Finn C Wiberg; Nicolai Wagtmann
Journal:  Nat Struct Biol       Date:  2003-01

4.  Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa.

Authors:  M Böhm; J St rzebecher; G Klebe
Journal:  J Med Chem       Date:  1999-02-11       Impact factor: 7.446

5.  Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes.

Authors:  M D Eldridge; C W Murray; T R Auton; G V Paolini; R P Mee
Journal:  J Comput Aided Mol Des       Date:  1997-09       Impact factor: 3.686

6.  Development and validation of a genetic algorithm for flexible docking.

Authors:  G Jones; P Willett; R C Glen; A R Leach; R Taylor
Journal:  J Mol Biol       Date:  1997-04-04       Impact factor: 5.469

Review 7.  Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides.

Authors:  R Mentlein
Journal:  Regul Pept       Date:  1999-11-30

8.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity.

Authors:  G Klebe; U Abraham; T Mietzner
Journal:  J Med Chem       Date:  1994-11-25       Impact factor: 7.446

Review 9.  Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.

Authors:  J J Holst; C F Deacon
Journal:  Diabetes       Date:  1998-11       Impact factor: 9.461

10.  Molecular cloning and sequence analysis of human dipeptidyl peptidase IV, a serine proteinase on the cell surface.

Authors:  Y Misumi; Y Hayashi; F Arakawa; Y Ikehara
Journal:  Biochim Biophys Acta       Date:  1992-07-15
View more
  7 in total

1.  In silico screening for identification of pyrrolidine derivatives dipeptidyl peptidase-IV inhibitors using COMFA, CoMSIA, HQSAR and docking studies.

Authors:  M C Sharma; S Jain; R Sharma
Journal:  In Silico Pharmacol       Date:  2017-10-23

2.  CoMFA and CoMSIA of diverse pyrrolidine analogues as dipeptidyl peptidase IV inhibitors: active site requirements.

Authors:  Vanangamudi Murugesan; Nidhi Sethi; Yenamandra S Prabhakar; Seturam B Katti
Journal:  Mol Divers       Date:  2010-08-25       Impact factor: 2.943

3.  Identification of diverse dipeptidyl peptidase IV inhibitors via structure-based virtual screening.

Authors:  Cui Li; Weiqiang Lu; Chunhua Lu; Wen Xiao; Xu Shen; Jin Huang; Guixia Liu; Yun Tang
Journal:  J Mol Model       Date:  2012-03-30       Impact factor: 1.810

4.  Exploring the potential mechanism of emetine against coronavirus disease 2019 combined with lung adenocarcinoma: bioinformatics and molecular simulation analyses.

Authors:  Kun Zhang; Ke Wang; Chaoguo Zhang; Xiuli Teng; Dan Li; Mingwei Chen
Journal:  BMC Cancer       Date:  2022-06-22       Impact factor: 4.638

5.  Covalent complexes of proteasome model with peptide aldehyde inhibitors MG132 and MG101: docking and molecular dynamics study.

Authors:  Siwei Zhang; Yawei Shi; Hongwei Jin; Zhenming Liu; Liangren Zhang; Lihe Zhang
Journal:  J Mol Model       Date:  2009-05-14       Impact factor: 1.810

6.  Molecular docking and 3D-QSAR studies on beta-phenylalanine derivatives as dipeptidyl peptidase IV inhibitors.

Authors:  Yan-Ke Jiang
Journal:  J Mol Model       Date:  2010-01-13       Impact factor: 1.810

7.  Refinement and 3D-QSAR Studies of Inhibitors of Cyclophilin A Containing Amide Linker.

Authors:  Feng Fan; Jin Zhu; Shuaishuai Ni; Jiagao Cheng; Yun Tang; Congmin Kang; Jian Li; Hualiang Jiang
Journal:  QSAR Comb Sci       Date:  2008-11-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.